Information for the public

NICE has assessed 5 tumour profiling tests (EndoPredict [EPclin score], Oncotype DX Breast Recurrence Score, Prosigna, MammaPrint and IHC4+C) to help the NHS decide whether to use these products.

Some people with early and locally advanced breast cancer may need further treatment after they have surgery. Online tools (such as PREDICT or the Nottingham Prognostic Index) are used to help guide what further treatment is offered after surgery, based on the cancer’s characteristics. Sometimes it’s not clear whether chemotherapy is needed, and tumour profiling tests can provide information to help people decide whether or not to have chemotherapy.

NICE has said that EndoPredict (EPclin score), Oncotype DX Breast Recurrence Score and Prosigna can be used to help the person and their clinician decide whether to have chemotherapy if there is an intermediate risk that the cancer will recur in other areas of the body. The tests can be used for people with oestrogen receptor-positive, human epidermal growth factor receptor 2-negative and lymph node-negative (including micrometastatic disease) breast cancer.

MammaPrint is not recommended because it is not cost effective. IHC4+C is not recommended because there is not enough evidence to show that the test is reliable.

ISBN: 978-1-4731-3129-3

This page was last updated: 19 December 2018